Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-synuclein is a protein that is the primary component of Lewy bodies, pathological aggregates found in neurodegenerative diseases known as synucleinopathies, including Parkinson's disease, Dementia with Lewy bodies, and Multiple System Atrophy. In the context of drug development, alpha-synuclein is being investigated as an antigen in active immunization strategies (vaccines) to stimulate the body's immune system to clear or prevent the accumulation of pathological alpha-synuclein. These vaccination approaches aim to induce both humoral (antibody) and cellular (T-cell) immune responses against alpha-synuclein, thereby reducing its accumulation, neuroinflammation, and neurodegeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-synuclein.